Bio-Rad Laboratories (BIO) Getting Somewhat Positive Press Coverage, Report Finds
Headlines about Bio-Rad Laboratories (NYSE:BIO) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bio-Rad Laboratories earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 47.721861927838 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern’s analysis:
- Critical Review: Palomar Medical Technologies (PMTI) vs. Bio-Rad Laboratories (BIO) (americanbankingnews.com)
- Analysts Anticipate Bio-Rad Laboratories, Inc. (BIO) Will Announce Earnings of $1.28 Per Share (americanbankingnews.com)
- Bio-Rad Laboratories (BIO) Downgraded by CL King (americanbankingnews.com)
- Cardiovascular Systems Portfolio Solid, Competition Rife (zacks.com)
- Latin America Cell Sorting Market Growth, Trends, And Forecasts (2016–2021) (emailwire.com)
Shares of Bio-Rad Laboratories (NYSE BIO) traded up $2.60 during midday trading on Friday, hitting $249.04. The company had a trading volume of 209,471 shares, compared to its average volume of 163,356. The company has a quick ratio of 2.77, a current ratio of 4.06 and a debt-to-equity ratio of 0.15. The firm has a market cap of $8,670.00, a PE ratio of 311.30, a price-to-earnings-growth ratio of 1.94 and a beta of 0.97. Bio-Rad Laboratories has a twelve month low of $186.98 and a twelve month high of $273.87.
A number of brokerages recently issued reports on BIO. CL King cut Bio-Rad Laboratories from a “buy” rating to a “neutral” rating in a report on Friday. Wells Fargo & Co restated an “outperform” rating and issued a $290.00 target price (up from $250.00) on shares of Bio-Rad Laboratories in a report on Wednesday, November 29th. Zacks Investment Research upgraded Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a report on Tuesday, November 7th. Finally, TheStreet upgraded Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a report on Monday, November 13th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $277.75.
In other news, VP James R. Stark sold 746 shares of the firm’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $270.51, for a total value of $201,800.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Crowley sold 1,000 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $258.39, for a total value of $258,390.00. Following the completion of the sale, the executive vice president now directly owns 2,492 shares of the company’s stock, valued at approximately $643,907.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,726 shares of company stock valued at $1,702,202. 28.29% of the stock is currently owned by insiders.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.